Hoth Therapeutics Stock Net Asset
| HOTH Stock | USD 0.82 0.02 2.38% |
Hoth Therapeutics fundamentals help investors to digest information that contributes to Hoth Therapeutics' financial success or failures. It also enables traders to predict the movement of Hoth Stock. The fundamental analysis module provides a way to measure Hoth Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hoth Therapeutics stock.
Hoth | Net Asset |
Hoth Therapeutics Company Net Asset Analysis
Hoth Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Hoth Therapeutics Net Asset | 9.52 M |
Most of Hoth Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hoth Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Hoth Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Hoth Therapeutics is extremely important. It helps to project a fair market value of Hoth Stock properly, considering its historical fundamentals such as Net Asset. Since Hoth Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Hoth Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Hoth Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Hoth Total Assets
Total Assets |
|
Based on the recorded statements, Hoth Therapeutics has a Net Asset of 9.52 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Hoth Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hoth Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hoth Therapeutics could also be used in its relative valuation, which is a method of valuing Hoth Therapeutics by comparing valuation metrics of similar companies.Hoth Therapeutics is currently under evaluation in net asset category among its peers.
Hoth Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Hoth Therapeutics from analyzing Hoth Therapeutics' financial statements. These drivers represent accounts that assess Hoth Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Hoth Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 56.7M | 29.3M | 14.7M | 9.3M | 4.9M | 4.7M | |
| Enterprise Value | 55.0M | 26.7M | 6.2M | 2.9M | (4.3M) | (4.1M) |
Hoth Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Hoth Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Hoth Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Hoth Therapeutics' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 82.9 K | Ubs Group Ag | 2024-06-30 | 43.4 K | Vanguard Group Inc | 2024-09-30 | 38.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 20 K | Tower Research Capital Llc | 2024-06-30 | 7.5 K | Royal Bank Of Canada | 2024-06-30 | 240 | Qube Research & Technologies | 2024-06-30 | 100.0 | Bank Of America Corp | 2024-06-30 | 35.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 9.0 | Wells Fargo & Co | 2024-06-30 | 2.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 |
Hoth Fundamentals
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | (2.19 M) | ||||
| Shares Outstanding | 6.9 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 5.30 % | ||||
| Number Of Shares Shorted | 620.78 K | ||||
| Price To Earning | (7.16) X | ||||
| Price To Book | 0.77 X | ||||
| EBITDA | (153.15 K) | ||||
| Net Income | (7.85 M) | ||||
| Cash And Equivalents | 11.62 M | ||||
| Cash Per Share | 9.02 X | ||||
| Total Debt | 55.16 K | ||||
| Debt To Equity | 2.01 % | ||||
| Current Ratio | 15.74 X | ||||
| Book Value Per Share | 1.09 X | ||||
| Cash Flow From Operations | (8.45 M) | ||||
| Short Ratio | 0.44 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 4.5 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 5.8 M | ||||
| Total Asset | 9.52 M | ||||
| Retained Earnings | (52.94 M) | ||||
| Working Capital | 8.75 M | ||||
| Current Asset | 448.84 K | ||||
| Current Liabilities | 312.22 K | ||||
| Net Asset | 9.52 M |
About Hoth Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hoth Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hoth Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hoth Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:Check out Hoth Therapeutics Piotroski F Score and Hoth Therapeutics Altman Z Score analysis. For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Return On Assets (0.46) | Return On Equity (0.83) |
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.